News

Lupin, Sandoz Launch Biosimilar Ranibizumab Across Europe

The launch follows the European Commission’s approval of Ranluspec in vial and pre-filled syringe presentations. The development marks another milestone in Lupin’s biosimilars business, alongside several key product launches, regulatory approvals, financial updates and leadership changes announced by the company this month.